Klinik Dr. Hancken
Hospital
Location:
diverse,
Germany (DE)
A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (Everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study of the IAG-N) (2022)
Hilser T, Gruenwald V, Bergmann L, Goebell P, Strauss A, Meiler J, Hartmann A, et al.
Conference contribution
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study) (2022)
Grünwald V, Hilser T, Meiler J, Goebell P, Ivanyi P, Strauss A, Hartmann A, et al.
Journal article